Westin St. Francis

Onkos Surgical to Present at Canaccord Genuity's 2024 Musculoskeletal Conference

Retrieved on: 
Monday, February 5, 2024
AAOS, Westin St. Francis, PST, American Academy, Trauma, Canaccord Genuity, Neoplasm, Printing, Conference

PARSIPPANY, N.J., Feb. 5, 2024 /PRNewswire/ -- Onkos Surgical, Inc., a rapidly growing orthopaedic company founded to address the complex clinical challenges associated with tumor, trauma, and revision surgery, announced today that it will present at Canaccord Genuity's 2024 Musculoskeletal Conference in San Francisco, CA. Patrick Treacy, Onkos CEO and co-founder, is scheduled to present a corporate overview and update on February 12th, at the Westin St. Francis at 11:00 a.m. PST. A webcast of this presentation will be available on the Company's website (https://onkossurgical.com).

Key Points: 
  • PARSIPPANY, N.J., Feb. 5, 2024 /PRNewswire/ -- Onkos Surgical, Inc., a rapidly growing orthopaedic company founded to address the complex clinical challenges associated with tumor, trauma, and revision surgery, announced today that it will present at Canaccord Genuity's 2024 Musculoskeletal Conference in San Francisco, CA.
  • Patrick Treacy, Onkos CEO and co-founder, is scheduled to present a corporate overview and update on February 12th, at the Westin St. Francis at 11:00 a.m. PST.
  • Onkos Surgical will also be exhibiting the Company's innovative solutions for musculoskeletal oncology and complex orthopaedic procedures at the 2024 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), being held February 12 - 16.
  • Onkos will showcase its portfolio of innovation, designed to support improved patient outcomes and experiences including virtual surgical planning, 3D modeling and printing, limb reconstructive implant design, and workflow optimization in Booth #5251 at the Moscone Convention Center, San Francisco, CA.

SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 10, 2024
Constant, Patient, PST, Forecasting, Research, Dasa, Liquid biopsy, Westin St. Francis, HRD, Cancer, GENETICS, Royal Marsden Hospital, Genomics, Conference, Platform, Webcast, J. P. Morgan, Sophia Genetics, FY, Q3, Growth

BOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA DDM™ Platform, in a presentation at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST.

Key Points: 
  • New customer count for 2023 includes 87 core genomics customers globally2, resulting in a current network of 750+ customers using SOPHiA DDM™ globally3.
  • New U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, as well as Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application.
  • I could not be more excited about the opportunities that lie ahead and SOPHiA GENETICS' ability to capitalize," said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS.
  • The SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution continues to be a strong driver of growth just two years after launch.

HealthEquity Announces Year-End HSA Sales Outlook; Presentation at J.P. Morgan Healthcare Conference; Investor Day

Retrieved on: 
Monday, January 8, 2024
Conference, CFO, HSA, Acquisition, Westin St. Francis, Health, Retirement, HQY, HealthEquity, Insurance, Growth, EVP, Cryptocurrency

Estimated HSA assets to be approximately $24.5 billion, up from $22.1 billion at the end of fiscal year 2023, with approximately $15 billion of HSA cash.

Key Points: 
  • Estimated HSA assets to be approximately $24.5 billion, up from $22.1 billion at the end of fiscal year 2023, with approximately $15 billion of HSA cash.
  • These estimates do not include the BenefitWallet HSA portfolio acquisition that is expected to close in fiscal 2025.
  • “The growth of Enhanced Rates is a win for our members and for HealthEquity,” said James Lucania, EVP and CFO.
  • HealthEquity also announced the registration links for its investor day are now open for institutional investors and analysts.

OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Health, Westin St. Francis, Conference, OPKO Health

MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco.

Key Points: 
  • MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco.
  • Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 10th at 3:45 p.m. Pacific time.

Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Friday, January 5, 2024
Standard of care, Westin St. Francis, Conference

WESTMINSTER, Colo., Jan. 5, 2024 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that Valeska Schroeder, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • WESTMINSTER, Colo., Jan. 5, 2024 /PRNewswire/ -- Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, today announced that Valeska Schroeder, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference.
  • The company presentation will take place on Monday, January 8, 2024, at 5:00 PM PST at the Westin St. Francis in the Mission Bay Room on the 32nd floor.

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

Retrieved on: 
Thursday, January 4, 2024
PIN, TS, EFS, Kite Pharma, Cancer, Conference, B-cell lymphoma, Disease, Steroid, CLL, Lymphocyte, First Line, CRS, Safety, News, Patient, Cyclophosphamide, MRD, AID, Cytokine release syndrome, Therapy, CF1, CD70, Biology, Westin St. Francis, Autoimmune disease, Renal cell carcinoma, SAN, Standard of care, Demand, Observation, RCC, CD19, Vaccine

“Until now, CAR T development has been defined by how autologous CAR Ts are made and used.

Key Points: 
  • “Until now, CAR T development has been defined by how autologous CAR Ts are made and used.
  • The standard of care after 1L treatment has been simply to “watch and wait” for the disease to relapse.
  • ALPHA3 builds on the growing understanding that administration of CAR T therapies to patients with low disease burden improves both safety and efficacy outcomes.
  • The 2024 Platform Vision Conference Call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.

OcuTerra Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Biotechnology, Pharmaceutical, Optical, Health, Therapy, Clinical trial, Diabetic retinopathy, Westin St. Francis, Conference, Diabetes, Disease, MD, Pharmaceutical industry

OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place on January 8-11, 2024 in San Francisco.

Key Points: 
  • OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch-and-wait” does not prevent or control the progression of disease, today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place on January 8-11, 2024 in San Francisco.
  • OcuTerra President and Chief Executive Officer Kerrie Brady will present on Thursday, January 11, at 9:00 am PT in the Mission Bay room at the Westin St. Francis.
  • OcuTerra recently announced the final patient visit in the Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast.
  • OcuTerra’s Chief Financial Officer, Bill Steinkrauss, and Chief Medical Officer, David J. Tanzer, MD, will also be in attendance at the conference.

Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Other Technology, Other Science, Health, Westin St. Francis, Conference, Atopic dermatitis, Protein, Learning, Cryogenic electron microscopy, Flagship Pioneering, Gateway, AMGN, Generative, Biomedicine, Biomarker, SARS-CoV-2, Safety, Therapy, Vaccine

Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.

Key Points: 
  • Mike Nally, Chief Executive Officer, will overview these updates, as well as share more about the company’s strategy to further strengthen its leadership in generative biology, at the 42nd Annual J.P. Morgan Healthcare Conference, which will be occurring from January 8-11 in San Francisco.
  • The presentation will take place on January 10 from 10:00-10:25am PST at the Golden Gate (32nd Floor) of The Westin St. Francis.
  • Deploying structure in the learning loop utilizing CryoEM to generate data for iterative learning which has shown faster, improved outcomes.
  • “We look forward to working even more closely together in order to deliver best-in-class therapies that address significant unmet patient needs.”

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
News, Cancer, Westin St. Francis, Conference, Kite Pharma, SAN, PIN, Therapy, Broadcasting

The 2024 Platform Vision conference call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.

Key Points: 
  • The 2024 Platform Vision conference call will be hosted on Thursday, January 4, 2024, at 2:00 p.m. PT/5:00 p.m.
  • David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will also present the 2024 Platform Vision at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 8:15 a.m. Pacific Time.
  • If you would like the option to ask a question on the conference call, please use this link to register.
  • Upon registering for the conference call, you will receive a personal PIN to access the call.

Cellarity to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Health, Infectious Diseases, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Research, Westin St. Francis, Conference, Flagship Pioneering

Cellarity Inc. , a life sciences company founded by Flagship Pioneering to fundamentally transform the way drugs are created and design medicines currently out of reach, announced today that Fabrice Chouraqui, CEO of Cellarity, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Thursday, January 11, 2024, at 7:30 a.m. PT.

Key Points: 
  • Cellarity Inc. , a life sciences company founded by Flagship Pioneering to fundamentally transform the way drugs are created and design medicines currently out of reach, announced today that Fabrice Chouraqui, CEO of Cellarity, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Thursday, January 11, 2024, at 7:30 a.m. PT.
  • A copy of the company’s presentation will be made available on the company’s website following the event.